Answers are grounded in this paper and cite their sources.
We report 12 patients with persistent viremia on oral antiretroviral therapy who were initiated on injectable cabotegravir/rilpivirine (iCAB/RPV) without oral lead-in. All patients achieved viral suppression without any virologic rebound. iCAB/RPV may be considered as an option for patients unable to maintain suppression on oral antiretroviral therapy.
No takes yet. Share an insight, caveat, or question.
Brock et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: